Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) and keeping the price target at $22.00.
Tazeen Ahmad has given his Buy rating due to a combination of factors including KalVista Pharmaceuticals’ strong preparation for the US commercial launch of sebetralstat. The company’s CEO, Ben Palleiko, expressed confidence in the launch readiness, highlighting educational initiatives targeting healthcare providers and favorable feedback from payors on the proposed pricing strategy. The clinical profile of sebetralstat, particularly its rapid symptom relief, has generated significant interest within the healthcare community, which is crucial for managing acute attacks.
Additionally, Tazeen Ahmad noted the stable regulatory path for sebetralstat, with no expected delays in the FDA review process. The company’s strategic positioning, with intellectual property maintained in the UK and manufacturing in the EU, minimizes potential tariff risks. KalVista’s plans for EU and Japanese market entries further bolster its growth prospects, supported by a lean operational strategy that does not require additional capital for international expansion. These factors collectively support the Buy rating, with a price objective of $22.
Ahmad covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Sarepta Therapeutics, and Ascendis Pharma. According to TipRanks, Ahmad has an average return of -5.3% and a 42.59% success rate on recommended stocks.
In another report released on April 8, Needham also maintained a Buy rating on the stock with a $28.00 price target.